title: In vivo assessment of intratumoral aspirin injection to treat hepatic tumors.
abstract: OBJECTIVE
  To study the antineoplastic efficacy of 10% aspirin intralesional injection on VX2 hepatic tumors in a rabbit model.
  
  
  METHODS
  Thirty-two male rabbits (age: 6-9 wk; body weight: 1700-2500 g) were inoculated with VX2 hepatic tumor cells (10(4) cells/rabbit) via supra-umbilical median laparotomy. On day 4 post-implantation, when the tumors were about 1 cm in diameter, the rabbits were randomly divided into the following groups (n = 8 each group) to assess early (24 h) and late (7 d) antineoplastic effects of intratumoral injection of 10% bicarbonate aspirin solution (experimental groups) in comparison to intratumoral injection of physiological saline solution (control groups): group 1, 24 h control; group 2, 24 h experimental; group 3, 7 d control; group 4, 7 d experimental. The serum biochemistry profile (measurements of glycemia, alkaline phosphatase, gamma-glutamyl transferase, aspartate aminotransferase, and alanine aminotransferase) and body weight measurements were obtained for all animals at the following time points: D0, before tumor implant; D4, day of treatment; D5, day of sacrifice for groups 1 and 2; D11, day of sacrifice for groups 3 and 4. Gross assessments of the abdominal and thoracic cavities were carried out upon sacrifice. The resected liver tissues, including hepatic tumors, were qualitatively (general morphology, signs of necrosis) and quantitatively (tumor area) assessed by histopathological analysis.
  
  
  RESULTS
  Gross examination showed no alterations, besides the left hepatic lobe tumors, had occurred in the thoracic and abdominal cavities of any animal at any time point evaluated. However, the features of the tumor foci were distinctive between the groups. Compared to the control groups, which showed normal unabated tumor progression, the aspirin-treated groups showed imprecise but limited tumor boundaries and a general red-white coloration (indicating hemorrhaging) at 24 h post-treatment, and development of yellow-white areas of a cicatricial aspect at 7 d after treatment. At all time points evaluated, all except one biochemical parameters tested within the reference range (P > 0.05); a significant increase was detected in the alkaline phosphatase level of the control group 3 on D11 (P < 0.05). At 24 h post-treatment, the aspirin-treated groups showed extensive coagulation necrosis accompanied by a remarkable absence of viable tumor foci; at 7 d after treatment, the tumors had completely disappeared in these animals and fibrous necrotic nodules had developed. In contrast, throughout the study course, the tumors of the control groups remained unchanged, showing tumor nodules without necrosis at the time point corresponding to 24 h post-treatment and increased amounts of tumor nodules at the time point corresponding to 7 d post-treatment. Quantitative analysis of the remaining tumor area revealed that the aspirin-treated groups had significantly smaller tumor foci at 24 h post-treatment (8.5% ± 0.7%) and at 7 d after treatment (11.0% ± 4.2%), compared to those in the control groups (24 h: 98.5% ± 1.5% and 7 d: 94.0% ± 2.7%; both, P < 0.005).
  
  
  CONCLUSIONS
  Intralesional injection of a 10% aspirin solution causes destruction of VX2 hepatic tumors in rabbits without evidence of relapse at 7 d after treatment administration.
authors.affiliation: Rogério Saad-Hossne, Fábio Vieira Teixeira, Rafael Denadai, Division of Coloproctology, Department of Surgery, Botucatu Medical School, University of the State of São Paulo, 18618-000 Botucatu-SP, Brazil.
authors.forename: Rogério
authors.initials: R
authors.lastname: Saad-Hossne
authors.forename: Fábio Vieira
authors.initials: FV
authors.lastname: Teixeira
authors.forename: Rafael
authors.initials: R
authors.lastname: Denadai
keywords: Antineoplastic; Aspirin; Hepatic tumor; Intralesional injection; Intratumoral injection; Rabbit; Therapy; VX2
references.citation: Cancer Res. 2007 Nov 1;67(21):10181-9
references.pmid: 17974958
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4575-80
references.pmid: 17925551
references.citation: BMJ. 2001 Feb 24;322(7284):477-80
references.pmid: 11222426
references.citation: Eur J Clin Invest. 2003 Oct;33(10):875-82
references.pmid: 14511359
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: World J Gastrointest Oncol. 2010 Oct 15;2(10):380-9
references.pmid: 21160889
references.citation: J Minim Invasive Gynecol. 2011 Nov-Dec;18(6):800-6
references.pmid: 22024267
references.citation: Invest Radiol. 2010 Jul;45(7):427-36
references.pmid: 20440211
references.citation: Ann Surg Oncol. 2009 Sep;16(9):2385-90
references.pmid: 19554377
references.citation: Anticancer Drugs. 2004 Jul;15(6):647-50
references.pmid: 15205611
references.citation: Blood. 1998 Aug 15;92(4):1406-14
references.pmid: 9694730
references.citation: Int J Clin Oncol. 2011 Oct;16(5):452-63
references.pmid: 21786210
references.citation: Colorectal Dis. 2011 Sep;13(9):e252-65
references.pmid: 21689362
references.citation: Pharm Unserer Zeit. 2009;38(4):306-13
references.pmid: 19572352
references.citation: Cancer. 1984 Mar 15;53(6):1397-404
references.pmid: 6692329
references.citation: Br J Cancer. 2011 Mar 29;104(7):1079-84
references.pmid: 21386839
references.citation: Circulation. 2011 Feb 22;123(7):768-78
references.pmid: 21343593
references.citation: Eur J Clin Invest. 2002 Nov;32(11):838-46
references.pmid: 12423325
references.citation: Semin Surg Oncol. 2003;21(1):13-8
references.pmid: 12923911
references.citation: Br J Cancer. 2006 Apr 10;94(7):982-99
references.pmid: 16538219
references.citation: J Comput Assist Tomogr. 2008 Sep-Oct;32(5):697-705
references.pmid: 18830097
references.citation: J Biol Chem. 2005 Dec 9;280(49):41047-56
references.pmid: 16199534
references.citation: Lancet. 1994 Jun 4;343(8910):1405-10
references.pmid: 7515134
references.citation: Expert Opin Pharmacother. 2002 Aug;3(8):1191-7
references.pmid: 12150696
references.citation: Acta Cir Bras. 2012 Nov;27(11):795-801
references.pmid: 23117612
references.citation: Regul Pept. 2003 Jul 15;114(2-3):101-7
references.pmid: 12832097
references.citation: Eur J Cancer. 1998 Nov;34(12):1935-40
references.pmid: 10023318
references.citation: Ultrasound Med Biol. 1995;21(5):649-55
references.pmid: 8525555
references.citation: Obstet Gynecol. 2001 Mar;97(3):423-7
references.pmid: 11239649
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):581-7
references.pmid: 21898115
references.citation: J Thromb Haemost. 2009 Jul;7 Suppl 1:258-61
references.pmid: 19630812
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
references.pmid: 20647400
references.citation: Cancer Res. 1988 Aug 15;48(16):4584-7
references.pmid: 3396009
references.citation: J Pharmacol Exp Ther. 1993 Jan;264(1):469-74
references.pmid: 7678651
references.citation: Eur J Cancer. 2013 Mar;49(4):938-45
references.pmid: 23079475
references.citation: Zhong Xi Yi Jie He Xue Bao. 2006 Nov;4(6):611-4
references.pmid: 17090378
references.citation: PLoS One. 2013;8(2):e57578
references.pmid: 23451245